Immunic (IMUX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $6.97, -1.83% vs the prior close of $7.10.
- Volume 366.21K shares, 1.1x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
IMUX dips 1.8% to $6.97. Closed at $6.97, -1.83% vs the prior close of $7.10. Day range $6.81–$7.92, opened at $7.10.
IMUX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — IMUX dips 1.8% to $6.97
- Closed at $6.97, -1.83% vs the prior close of $7.10. Day range $6.81–$7.92, opened at $7.10.
- Volume was 366.21K shares, 1.1x its 50-day average of 341.88K.
- Price is -41.5% vs its 50-day average ($11.91) and -39.1% vs its 200-day average ($11.44).
- 52-week range $5.06–$17.43; today's close sits at 15% of that range, 60.0% below the 52-week high.
Oct 15, 2026 — IMUX jumps 6.6% to $7.10
- Closed at $7.10, +6.61% vs the prior close of $6.66. Day range $6.59–$7.14, opened at $6.64.
- Volume was 285.10K shares, 0.8x its 50-day average of 341.71K.
- Price is -41.2% vs its 50-day average ($12.07) and -37.9% vs its 200-day average ($11.43).
- 52-week range $5.06–$17.43; today's close sits at 16% of that range, 59.3% below the 52-week high.
Oct 14, 2026 — IMUX slides 3.3% to $6.66, a 6-month low, 3 down days in a row
- Closed at $6.66, -3.34% vs the prior close of $6.89. Day range $6.35–$7.03, opened at $6.78.
- Volume was 438.00K shares, 1.3x its 50-day average of 337.94K.
- Price is -45.4% vs its 50-day average ($12.20) and -41.7% vs its 200-day average ($11.42).
- 52-week range $5.06–$17.43; today's close sits at 13% of that range, 61.8% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — IMUX slides 13.3% to $6.89, a 6-month low
- Closed at $6.89, -13.33% vs the prior close of $7.95. Day range $6.82–$8.14, opened at $7.96.
- Volume was 572.80K shares, 1.7x its 50-day average of 329.88K.
- Price is -44.2% vs its 50-day average ($12.35) and -39.7% vs its 200-day average ($11.42).
- 52-week range $5.06–$17.43; today's close sits at 15% of that range, 60.5% below the 52-week high.
Oct 12, 2026 — IMUX dips 2.9% to $7.95
- Closed at $7.95, -2.93% vs the prior close of $8.19. Day range $7.92–$8.44, opened at $8.19.
- Volume was 152.10K shares, 0.5x its 50-day average of 329.75K — lighter than usual.
- Price is -36.4% vs its 50-day average ($12.50) and -30.4% vs its 200-day average ($11.41).
- 52-week range $5.06–$17.43; today's close sits at 23% of that range, 54.4% below the 52-week high.
Oct 9, 2026 — IMUX jumps 8.3% to $8.19
- Closed at $8.19, +8.33% vs the prior close of $7.56. Day range $7.47–$8.60, opened at $7.63.
- Volume was 510.90K shares, 1.6x its 50-day average of 320.87K.
- Price is -35.1% vs its 50-day average ($12.62) and -28.2% vs its 200-day average ($11.40).
- 52-week range $5.06–$17.43; today's close sits at 25% of that range, 53.0% below the 52-week high.
Oct 8, 2026 — IMUX dips 0.9% to $7.56, a 6-month low on 1.9x normal volume
- Closed at $7.56, -0.92% vs the prior close of $7.63. Day range $7.25–$7.65, opened at $7.65.
- Volume was 588.80K shares, 1.9x its 50-day average of 310.94K — unusually heavy trading.
- Price is -40.6% vs its 50-day average ($12.73) and -33.6% vs its 200-day average ($11.39).
- 52-week range $5.06–$17.43; today's close sits at 20% of that range, 56.6% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — IMUX dips 2.4% to $7.63, a 6-month low
- Closed at $7.63, -2.43% vs the prior close of $7.82. Day range $7.49–$7.90, opened at $7.80.
- Volume was 381.20K shares, 1.2x its 50-day average of 305.38K.
- Price is -40.6% vs its 50-day average ($12.84) and -33.0% vs its 200-day average ($11.38).
- 52-week range $5.06–$17.43; today's close sits at 21% of that range, 56.2% below the 52-week high.
Oct 6, 2026 — IMUX slides 3.1% to $7.82, a 6-month low
- Closed at $7.82, -3.10% vs the prior close of $8.07. Day range $7.77–$8.17, opened at $8.13.
- Volume was 347.80K shares, 1.2x its 50-day average of 300.72K.
- Price is -39.6% vs its 50-day average ($12.96) and -31.2% vs its 200-day average ($11.37).
- 52-week range $5.06–$17.43; today's close sits at 22% of that range, 55.1% below the 52-week high.
Oct 5, 2026 — IMUX rises 1.4% to $8.07
- Closed at $8.07, +1.38% vs the prior close of $7.96. Day range $7.70–$8.17, opened at $8.00.
- Volume was 490.20K shares, 1.7x its 50-day average of 294.03K.
- Price is -38.3% vs its 50-day average ($13.08) and -29.0% vs its 200-day average ($11.36).
- 52-week range $5.06–$17.43; today's close sits at 24% of that range, 53.7% below the 52-week high.
Oct 2, 2026 — IMUX slides 7.9% to $7.96, a 6-month low on 2.5x normal volume
- Closed at $7.96, -7.87% vs the prior close of $8.64. Day range $7.76–$8.87, opened at $8.69.
- Volume was 723.00K shares, 2.5x its 50-day average of 284.35K — unusually heavy trading.
- Price is -39.6% vs its 50-day average ($13.18) and -29.9% vs its 200-day average ($11.35).
- 52-week range $5.06–$17.43; today's close sits at 23% of that range, 54.3% below the 52-week high.
IMUX latest news & SEC filings
Every SEC filing by or about IMUX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 1, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Sep 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$34.10M (prior year -$26.82M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.80 (prior year -$2.03) (loss narrowed vs Jun 30, 2025)
Aug 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 10, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 6, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade IMUX
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Feb 26, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.40% (largest 13.6%). That is a volatile stock.
- Liquidity: about 464.12K shares (≈$3.23M) trade per day on average.
- 52-week position: $6.97 vs a range of $5.06–$17.43 (15% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:10 on Apr 27, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Sep 11, 2026; 8-K Sep 9, 2026; 8-K Aug 11, 2026.
- Share count: 13.64M shares outstanding (Jul 31, 2026), -86.2% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
IMUX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 7.10 | 7.92 | 6.81 | 6.97 | 366.21K |
| Oct 15, 2026 | 6.64 | 7.14 | 6.59 | 7.10 | 285.10K |
| Oct 14, 2026 | 6.78 | 7.03 | 6.35 | 6.66 | 438.00K |
| Oct 13, 2026 | 7.96 | 8.14 | 6.82 | 6.89 | 572.80K |
| Oct 12, 2026 | 8.19 | 8.44 | 7.92 | 7.95 | 152.10K |
| Oct 9, 2026 | 7.63 | 8.60 | 7.47 | 8.19 | 510.90K |
| Oct 8, 2026 | 7.65 | 7.65 | 7.25 | 7.56 | 588.80K |
| Oct 7, 2026 | 7.80 | 7.90 | 7.49 | 7.63 | 381.20K |
| Oct 6, 2026 | 8.13 | 8.17 | 7.77 | 7.82 | 347.80K |
| Oct 5, 2026 | 8.00 | 8.17 | 7.70 | 8.07 | 490.20K |
| Oct 2, 2026 | 8.69 | 8.87 | 7.76 | 7.96 | 723.00K |
| Oct 1, 2026 | 9.30 | 9.47 | 8.60 | 8.64 | 557.70K |
| Sep 30, 2026 | 9.00 | 9.44 | 8.74 | 9.30 | 448.50K |
| Sep 29, 2026 | 9.60 | 9.63 | 8.87 | 8.91 | 435.00K |
| Sep 28, 2026 | 9.32 | 9.94 | 9.09 | 9.51 | 660.40K |
| Sep 25, 2026 | 9.42 | 9.50 | 9.12 | 9.35 | 316.60K |
| Sep 24, 2026 | 9.32 | 9.53 | 9.09 | 9.32 | 448.40K |
| Sep 23, 2026 | 10.85 | 11.12 | 9.36 | 9.37 | 660.60K |
| Sep 22, 2026 | 10.95 | 11.28 | 10.76 | 10.84 | 430.50K |
| Sep 21, 2026 | 10.86 | 11.07 | 10.47 | 10.83 | 468.60K |
About Immunic
Immunic (IMUX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW YORK, United States. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1280776.
IMUX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Value Fund Ii Lp Biotechnology | See Explanation of Responses | Sep 18, 2026 |
| Value Fund L P Biotechnology | See Explanation of Responses | Sep 18, 2026 |
| Michael W Bonney | Director | Jun 29, 2026 |
| Gp Holdings Llc Bvf | See Explanation of Responses | Sep 18, 2026 |
| I Gp Llc Bvf | See Explanation of Responses | Sep 18, 2026 |
| Ii Gp Llc Bvf | See Explanation of Responses | Sep 18, 2026 |
| Inc/Il Bvf | See Explanation of Responses | Sep 18, 2026 |
| Partners L P/Il Bvf | See Explanation of Responses | Sep 18, 2026 |
| Partners Os Ltd. Bvf | See Explanation of Responses | Sep 18, 2026 |
| Value Trading Fund Os Lp Biotechnology | See Explanation of Responses | Sep 18, 2026 |
| Jon Congleton | Director | Jul 7, 2026 |
| Tamar D Howson | Director | Jun 29, 2026 |
| Mark N Lampert | See Explanation of Responses | Sep 18, 2026 |
| Robert Thorvald Nagel | Director | Sep 18, 2026 |
| Joerg Neermann | Director | Jul 7, 2026 |
| Barclay A Phillips | Director | Jul 7, 2026 |
| Elena Ridloff | Director | Aug 10, 2026 |
| Richard Alan Rudick | Director | Jul 7, 2026 |
| Simona Skerjanec | Director | Jul 7, 2026 |
| Daniel Vitt | Director | Jun 29, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Erik Lundgren | Chief Executive Officer | Jun 1, 2026 |
| Michael A. Panzara | Chief Medical Officer | Apr 29, 2026 |
| Jason Tardio | President and COO | Jun 29, 2026 |
| Glenn Whaley | Chief Financial Officer | Jun 29, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
IMUX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-97.17M | -0.62 | $-85.81M |
| Dec 31, 2024 | — | $-100.51M | -1.00 | $-84.77M |
| Dec 31, 2023 | — | $-93.61M | -2.11 | $-70.83M |
| Dec 31, 2022 | — | $-120.41M | -3.78 | $-65.14M |
| Dec 31, 2021 | — | $-92.94M | -3.93 | $-83.23M |
Latest balance sheet: total assets $159.17M, total liabilities $31.59M, cash $155.10M (as of Jun 30, 2026).
IMUX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $15.48 |
| May 13, 2026 | 8-K Item 2.02 (results) | $12.95 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $9.48 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $7.13 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $9.02 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $11.80 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Feb 22, 2024 | 8-K Item 2.02 (results) | — |
| Nov 14, 2023 | 8-K Item 2.02 (results) | — |
| Aug 3, 2023 | 8-K Item 2.02 (results) | — |
| May 11, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on IMUX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.